Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
1. Novo Nordisk's Ozempic shows significant heart health benefits and weight loss. 2. Analysts upgraded NVO from Hold to Buy, indicating 20% upside potential. 3. NVO is forming a technical base similar to UnitedHealth Group's recovery. 4. Improving clinical data supports new market opportunities and demand. 5. Sentiment around NVO is shifting positively, reflecting market optimism.